#1 Clinical Trials Search in Europe

Auto4

This article discusses a clinical trial investigating the long-term safety and effectiveness of AUTO4, a type of CAR T-cell therapy. The study focuses on patients who have previously received this innovative treatment for conditions such as acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, and systemic lupus erythematosus. The trial aims to monitor patients for up to 15 years to assess the long-term impacts and potential risks associated with AUTO4 therapy.

Table of Contents

What is AUTO4?

AUTO4 is an innovative medical treatment classified as a CAR T-cell therapy. CAR T-cell therapy is a type of treatment in which a patient’s own immune cells (T-cells) are modified in a laboratory to better fight cancer or other diseases. AUTO4 is administered through an intravenous infusion, which means it’s delivered directly into the bloodstream through a vein.[1]

Medical Conditions Treated

AUTO4 is being studied for the treatment of several serious medical conditions, including:[1]

  • Acute lymphoblastic leukemia (ALL): A type of blood cancer that affects white blood cells called lymphocytes.
  • Non-Hodgkin’s lymphoma (NHL): A group of blood cancers that develop in the lymphatic system.
  • Systemic lupus erythematosus (SLE): An autoimmune disease where the body’s immune system attacks its own tissues.

How AUTO4 Works

AUTO4 is a personalized treatment made from a patient’s own T-cells. Here’s a simplified explanation of how it works:[1]

  1. T-cells are collected from the patient’s blood.
  2. In a laboratory, these T-cells are genetically modified using viral vectors (special viruses that can insert new genes into cells).
  3. The modified T-cells are equipped with a chimeric antigen receptor (CAR), which helps them recognize and attack specific cancer cells or harmful immune cells.
  4. The modified T-cells, now called AUTO4, are multiplied in the lab.
  5. The AUTO4 cells are then infused back into the patient’s bloodstream, where they can seek out and destroy targeted cells.

Clinical Trial Overview

A clinical trial is currently underway to study the long-term effects of AUTO4 and other similar CAR T-cell therapies developed by Autolus Limited. The main goal of this trial is to assess the long-term safety of these treatments.[1]

The trial also aims to investigate several important aspects:

  • B-cell/T-cell aplasia: A condition where the body doesn’t produce enough B-cells or T-cells, which are important for the immune system.
  • The effectiveness of AUTO4 in patients who started the treatment before their disease got worse.
  • How long the modified T-cells (with the CAR) stay in the patient’s body.
  • Whether there’s any emergence of replication-competent retroviruses or lentiviruses, which could potentially cause health issues.
  • Insertional mutagenesis: A rare but potential risk where the genetic modification could lead to new mutations in the patient’s cells.

Eligibility Criteria

To participate in this long-term follow-up study, patients must meet the following criteria:[1]

  • Have previously received an AUTO CAR T-cell therapy (like AUTO4) in a treatment study.
  • Provide informed consent to participate in the long-term follow-up study.
  • Be able to comply with the study requirements.

Importantly, there are no exclusion criteria for this study, meaning that all patients who meet the above requirements can participate.

Safety and Monitoring

Patient safety is a top priority in this study. Participants will be closely monitored for up to 15 years after receiving their first AUTO CAR T-cell therapy infusion. The monitoring schedule is as follows:[1]

  • Every 3 months for the first year after infusion
  • Every 6 months for the next 4 years
  • Annually for the following 10 years

During these check-ups, doctors will look for any serious side effects related to the therapy, new cancers, or other important health events.

Potential Benefits and Risks

While AUTO4 shows promise in treating serious conditions like leukemia, lymphoma, and lupus, it’s important to understand both the potential benefits and risks:[1]

Potential benefits:

  • Effective treatment for cancers and autoimmune diseases that haven’t responded to other therapies
  • Personalized treatment using the patient’s own immune cells
  • Possibility of long-lasting remission or control of the disease

Potential risks:

  • Serious side effects related to the CAR T-cell therapy
  • Possibility of developing new cancers
  • Long-term effects on the immune system, such as B-cell or T-cell aplasia
  • Rare but potential risk of insertional mutagenesis

It’s crucial for patients to discuss these potential benefits and risks thoroughly with their healthcare providers before considering AUTO4 or participating in related clinical trials.

Aspect Details
Study Drug AUTO4 (CAR T-cell therapy)
Main Objective Long-term safety assessment
Target Conditions Acute lymphoblastic leukemia, Non-Hodgkin’s lymphoma, Systemic lupus erythematosus
Study Duration Up to 15 years post-infusion
Key Endpoints Serious adverse events, new malignancies, overall survival, duration of response
Monitoring Schedule Every 3 months (Year 1), Every 6 months (Years 2-5), Annually (Years 6-15)

FAQ

  • What is AUTO4? AUTO4 is a type of CAR T-cell therapy, which involves genetically modifying a patient's own T-cells to target and fight cancer or other diseases. It is administered through intravenous infusion.
  • How long does the clinical trial last? The clinical trial follows patients for up to 15 years after their first AUTO4 infusion, or until death, whichever comes first.
  • What conditions is AUTO4 being studied for? AUTO4 is being studied for potential malignancies, including acute lymphoblastic leukemia, non-Hodgkin's lymphoma, and systemic lupus erythematosus.
  • What are the main objectives of this clinical trial? The main objectives are to assess long-term safety, monitor for new malignancies, evaluate B-cell/T-cell aplasia, measure clinical efficacy, and check for potential risks such as replication-competent viruses and insertional mutagenesis.
  • How often are patients monitored during the study? Patients are monitored every 3 months for the first year after infusion, then every 6 months for the next 4 years, and annually for the following 10 years.

Ongoing Clinical Trials on Auto4

  • Long-term Safety Study of AUTO4 and Rituximab in Patients with Potential Malignancy Treated with Autologous CAR T Cell Therapy

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • CAR T-cell therapy: A type of treatment that uses a patient's own T-cells (a type of immune cell) that have been genetically modified to better recognize and attack cancer cells.
  • Acute lymphoblastic leukemia: A type of cancer that affects the blood and bone marrow, causing rapid growth of abnormal white blood cells.
  • Non-Hodgkin's lymphoma: A type of cancer that starts in the lymphatic system, which is part of the body's immune system.
  • Systemic lupus erythematosus: An autoimmune disease where the body's immune system mistakenly attacks healthy tissues in many parts of the body.
  • B-cell/T-cell aplasia: A condition where the body stops producing B-cells or T-cells, which are important types of white blood cells in the immune system.
  • Replication competent retrovirus/lentivirus: Viruses used in gene therapy that have regained the ability to reproduce and spread, potentially causing unwanted effects.
  • Insertional mutagenesis: A process where new genetic material is inserted into a person's DNA, potentially causing harmful mutations.
  • Progression-free survival: The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • Vector copy number: A measure of how many copies of the therapeutic gene have been inserted into the patient's cells.

References

  1. http://clinicaltrials.eu/trial/long-term-safety-study-of-auto4-and-rituximab-in-patients-with-potential-malignancy-treated-with-autologous-car-t-cell-therapy/